Application | Comment | Organism |
---|---|---|
medicine | inhibition of PDE10A represents an important new target for the treatment of schizophrenia and related disorders of basal ganglia function | Rattus norvegicus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2-[[4-[4-pyridin-4-yl-1-(2,2, 2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline succinic acid | potent inhibitor | Rattus norvegicus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | Rattus norvegicus | PDE10A regulates both cAMP and cGMP signaling cascades to impact early signal processing in the corticostriatothalamic circuit | ? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Rattus norvegicus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
corpus striatum | PDE10A is highly expressed in the medium spiny neurons of the striatum | Rattus norvegicus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
3',5'-cAMP + H2O | - |
Rattus norvegicus | 5'-AMP | - |
? | |
3',5'-cGMP + H2O | - |
Rattus norvegicus | 5'-GMP | - |
? | |
additional information | PDE10A regulates both cAMP and cGMP signaling cascades to impact early signal processing in the corticostriatothalamic circuit | Rattus norvegicus | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
cyclic nucleotide phosphodiesterase 10A | - |
Rattus norvegicus |
PDE10A | - |
Rattus norvegicus |
phosphodiesterase 10A | - |
Rattus norvegicus |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.000001 | - |
the IC50 of the compound for inhibition of PDE10A in vitro is less than 1 nM | Rattus norvegicus | 2-[[4-[4-pyridin-4-yl-1-(2,2, 2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline succinic acid |